Emerging targeted therapies for castration-resistant prostate cancer

Related Experiment Video

Updated: May 21, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Vincenzo Adamo1, Laura Noto, Tindara Franchina

  • 1Integrated Therapies in Oncology Unit, Department of Human Pathology, University of Messina Messina, Italy.

Frontiers in Endocrinology
|June 6, 2012
PubMed

Insights

New targeted therapies are emerging for castration-resistant prostate cancer (CRPC), offering hope beyond limited options. Ongoing trials investigate novel agents and combinations to personalize treatment for advanced prostate cancer.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Limited therapeutic options historically available for castration-resistant prostate cancer (CRPC).
  • Recent approvals (since 2010) include sipuleucel-T, cabazitaxel, abiraterone, and denosumab for CRPC.
  • Numerous novel agents are currently under investigation in clinical trials for CRPC.

Purpose of the Study:

  • To provide an updated review of targeted therapies for castration-resistant prostate cancer (CRPC).
  • To summarize data from literature and congress reports up to December 2011.

Main Methods:

  • Literature review and congress report analysis.
  • Focus on targeted therapies in advanced stages of clinical development.
  • Categorization of agents by mechanism of action (androgen signaling, alternative pathways, anti-angiogenesis, bone microenvironment, immunotherapy).

Main Results:

  • Targeted therapies in advanced development include novel androgen signaling inhibitors, alternative pathway inhibitors, anti-angiogenic agents, bone-targeting agents, and immunotherapeutics.
  • Radium-223 and MDV3100 have demonstrated survival advantages in Phase III trials, nearing clinical introduction.
  • Results are pending for Phase III studies of monotherapy agents (e.g., TAK-700, cabozantinib) and combinations with docetaxel (e.g., custirsen, aflibercept).

Conclusions:

  • Emerging therapies show promise for castration-resistant prostate cancer (CRPC).
  • Optimal timing, combination, and sequencing of these novel therapies require further investigation.
  • Identification of response/resistance markers is crucial for personalized CRPC treatment.
Keywords:
anti-angiogenic therapybone targeting therapycastration-resistant prostate cancerhormonal therapyimmunotherapytargeted therapy

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...